Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.
The chart above compares analysts’ recommendations over the last 12 months.
Novartis’s stock price has risen ~11.0% over the last 12 months. Analysts’ estimates show that the stock has the potential to return ~20.8% over the next 12 months. Analysts’ recommendations show a 12-month target price of $98.06 per share compared to the stock’s price of $81.17 on April 16, 2018.
As of April 17, 2018, four analysts are tracking Novartis’s ADR (American depositary receipt). Of these, one analyst recommends a “strong buy,” one recommends a “buy,” one recommends a “hold,” and one recommends a “sell.” The consensus rating for Novartis’s ADR is 2.50, which represents a moderate “buy” for value investors.
There are 27 analysts tracking Novartis stock. Of these, seven analysts recommend “strong buys,” nine recommend “buys,” eight recommend “holds,” and three recommend “sells.” Changes in analysts’ estimates and recommendations are based on the changing trends in a stock’s price and a company’s performance. The consensus rating for Novartis is 2.27, which represents a moderate “buy” for long-term growth investors as well as value investors.
The Vanguard FTSE All-World ex-US ETF (VEU) holds 7.4% of its total investments in healthcare companies. VEU holds 0.8% in Novartis AG, 0.4% in Novo Nordisk (NVO), 0.4% in Sanofi (SNY), and 0.4% in AstraZeneca (AZN).
Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!